Defining Treatment-Resistant Depression in Adults

How Do Current Guidelines Fall Short in Real-World Practice?

On October 5, 2026, psychiatrists Ben Yudkoff and Gene Dolgin discussed the evolving understanding of treatment-resistant depression in adults during a video series episode. Their conversation focused on clarifying diagnostic criteria and identifying barriers to effective care. They emphasized the need for standardized definitions to improve clinical consistency and research accuracy across healthcare settings.

The experts noted that treatment-resistant depression is often diagnosed after two adequate antidepressant trials fail to produce remission, though definitions vary widely in practice. They highlighted how comorbidities, medication adherence, and psychosocial factors complicate assessment and contribute to misclassification. Dolgin pointed out that inconsistent screening tools lead to disparities in diagnosis, particularly in primary care environments where time and resources are limited.

What Steps Can Clinicians Take to Improve Accuracy?

Yudkoff explained that while major psychiatric associations offer guidelines, few account for individual patient variability in metabolism, trauma history, or social determinants of health. He cited cases where patients labeled as treatment-resistant actually had undiagnosed bipolar disorder or substance use issues masking depression symptoms. The clinicians stressed that rushed evaluations in busy clinics often overlook these nuances, resulting in inappropriate treatment escalation.

The experts recommended incorporating structured interviews, longitudinal symptom tracking, and input from family members when assessing treatment resistance. They advocated for routine use of validated scales like the MADRS or PHQ-9 at multiple intervals to objectively measure response. Dolgin suggested that collaborative care models involving pharmacists and therapists could reduce diagnostic errors and prevent premature labeling of patients as non-responsive.

What qualifies as an adequate antidepressant trial? An adequate trial typically involves at least six to eight weeks of treatment at a therapeutic dose, with adherence confirmed through patient report or pharmacy records.

Frequently Asked Questions

Why is defining treatment-resistant depression important for research? Clear definitions ensure study populations are comparable, which increases the validity of findings and helps identify which interventions work best for specific subgroups.

Can lifestyle changes influence whether depression is considered treatment-resistant? Yes, factors like sleep quality, exercise, and nutrition can significantly affect mood and medication response, so addressing them may improve outcomes before concluding resistance.